Juan Cordova, principal scientist in bioconjugation, Abzena Cordova began his presentation by introducing Abzena as a global network that provides an integrated solution for the development and manufacture of biotherapies, including antibody–drug conjugates (ADCs). The company operates three different facilities, in which it develops and manufactures complex small molecules as well as bioconjugate therapies. ADCs are one of the most complex examples of biotherapies approved by the US Food and Drug Administration (FDA) on the market today because they comprise…